Efficient conversion of Biginelli 3,4-dihydropyrimidin-2(1H)-one to pyrimidines via PyBroP-mediated coupling

Journal of Organic Chemistry

Volumn 70, Issue 5, 2005, Pages 1957-1960

  Kang, Fu An ^a   Kodah, Jason ^a   Guan, Qunying ^a   Li, Xiaobing ^a   Murray, William V ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEHYDROGENATION; ORGANIC COMPOUNDS; REACTION KINETICS; SYNTHESIS (CHEMICAL);

DIVERSITY ORIENTED SYNTHESIS; KAPPE DEHYDROGENATION; PYRIMIDINES; TWO-STEP PROCEDURE;

PHASE TRANSITIONS;

2 (N BENZYLAMINO) 4 PHENYL 6 METHYLPYRIMIDIN 2(1H) ONE 5 CARBOXYLIC ACID METHYL ESTER; 2 (N METHYLMETHANESULFONYLAMINO) 4 PHENYL 6 METHYLPYRIMIDIN 2(1H) ONE 5 CARBOXYLIC ACID METHYL ESTER; 3,4 DIHYDROPYRIMIDIN 2(1H) ONE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BIGINELLI REACTION; DEHYDROGENATION; PYRIMIDINE SYNTHESIS; SYNTHESIS;

HYDROGENATION; MOLECULAR STRUCTURE; PYRIMIDINES; PYRIMIDINONES;

EID: 14544306016     PISSN: 00223263     EISSN: None     Source Type: Journal    
DOI: 10.1021/jo040281j     Document Type: Article

References (41)

1. Biginelli, P. Gazz. Chim. Ital. 1893, 23, 360.
2. Kappe, C. O. Tetrahedron 1993, 49, 6937.
3. (a) Kappe, C. O. Acc. Chem. Res. 2000, 33, 879.
4. (b) Bussolari, J. C.; McDonnell, P. A. J. Org. Chem. 2000, 65, 6777.
5. (c) Byk, G.; Gottlieb, H. E.; Herscovici, J.; Mirkin, F. J. Comb. Chem. 2000, 2, 732.
6. (d) Dondoni, A.; Massi, A.; Sabbatini, S.; Bertolasi, V. J. Org. Chem. 2002, 67, 6979.
7. (e) Dzvinchuk, I. B.; Makitruk, T. V.; Lozinskii, M. O. Chem. Heterocycl. Comput. 2003, 39, 455.
8. (f) Dondoni, A.; Massi, A.; Minghini E.; Sabbatini, S.; Bertolasi, V. J. Org. Chem. 2003, 68, 6172.
9. (g) Abelman, M. M.; Smith, S. C.; James, D. R. Tetrahedron Lett. 2003, 44, 4559.
10. (h) Gong, D.; Zhang, L.; Yuan, C. Heteroatom Chem. 2003, 14, 13.
11. (i) Kappe, C. O. QSAR Comb. Sci. 2003, 22, 630.
12. (j) Dondoni, A.; Massi, A. Mol. Div. 2003, 6, 261.
13. (k) Kappe, C. O.; Stadler, A. Org. React. 2004, 63, 1.
14. (l) Byk, G.; Kabha, E. J. Comb. Chem. 2004, 6, 596.
15. (m) Bandyopadhyay, C.; Nag, P. P.; Sur, K. R.; Patra, R.; Banerjee, S.; Sen, A.; Ghosh, T. J. Indian Chem. Soc. 2004, 81, 132.
16. (n) Shaabani, A.; Bazgir, A.; Bijanzadeh, H. R. Mol. Div. 2004, 8, 141.
17. (a) Kappe, C. O. Eur. J. Med. Chem. 2000, 35, 1043.
18. (b) Deres, K.; Schroder, C. H.; Paessens, A.; Goldmann, S.; Hacker, H. J.; Weber, O.; Kraemer, T.; Niewoehner, U.; Pleiss, U.; Stoltefuss, J.; Graef, E.; Koletzki, D.; Masantschek, R. N. A.; Reimann, A.; Jaeger, R.; Groß, R.; Beckermann, B.; Schlemmer, K.-H.; Haebich, D.; Rubsamen-Waigmann, H. Science 2003, 299, 893.
19. (c) Lengar, A.; Kappe, C. O. Org. Lett. 2004, 6, 771.
20. (a) Snider, B. B.; Shi, Z. J. Org. Chem. 1993, 58, 3828.
21. (b) Patil, A. D.; Kumar, N. V.; Kokke, W. C.; Bean, M. F.; Freyer, A. J.; De Brosse, C.; Mai, S.; Truneh, A.; Gaulkner, D. J.; Carte, B.; Breen, A. L.; Hertzberg, R. P.; Johnson, R. K.; Westly, J. W.; Potts, B. C. J. Org. Chem. 1995, 60, 1182.
22. (c) Overman, L. E.; Rabinowitz, M. H.; Renhowe, P. A. J. Am. Chem. Soc. 1995, 117, 2675.
23. (d) Aron, Z. D.; Overman, L. E. Chem. Commun. 2004, 253.
24. For representative drugs and biologicals containing pyrimidines (over 80 examples), such as amprolium, bispyribac, cetotiamine, diaveridine, ethirimol, fenarimol, glymidine, ipsapirone, lesopitron, mepanipyrin, nimustine, oxythiamine, peplomycin, quinapyramine, rimsulfuron, sulfabromomethazine,and tandospirone, see: The Merck Index, An Encyclopedia of Chemicals, Drugs and Biologicals, 13th ed.; Merck & Co., Inc.: Whitehouse Station, 2001.
25. Eynde, J. J. V.; Audiart, N.; Canonne, V.; Michel, S.; Haverbeke, Y. V.; Kappe, C. O. Heterocycles 1997, 45, 1967.
26. Puchala, A.; Belaj, F.; Bergman, J.; Kappe, C. O. J. Heterocycl. Chem. 2001, 38, 1345.
27. Kappe, C. O.; Roschger, P.; J. Heterocycl. Chem. 1989, 26, 55.
28. (a) Matsushita, A.; Oda, M.; Kawachi, Y.; Chika, J. WO 03006439, 2003.
29. (b) Watanabe, M.; Koike, H.; Ishiba, T.; Okada, T.; Seo, S.; Hirai, K. Bioorg. Med. Chem. 1997, 5, 437.
30. For a preliminary communication of this study, see: Kang, F.-A.; Murray, W. V. Abstracts of Papers, 228th National Meeting of the American Chemical Society, Philadelphia, PA.; American Chemical Society: Washington, DC, 2004; ORGN 702.
31. Hu, E. H.; Sidler, D. R.; Dolling, U.-H. J. Org. Chem. 1998, 63, 3454.
32. 6, see the Supporting Information.
33. (a) Coste, J.; Le-Nguyen, D.; Castro, B. Tetrahedron Lett. 1990, 31, 205.
34. (b) Coste, J.; Frerot, E.; Jouin, P. Tetrahedron Lett. 1991, 32, 1967.
35. (c) The coupling reactions by directly using commercial PyBOP or PyBroP usually produce about 5% of the pyrolidine-containing side-product 3c (Table 2), which is attributed to the presence of a small amount of pyrrolidine as a contaminant to the commercial phosphonium salts. This side reaction does not occur when the reagents are recrystallized before their use in the coupling reaction. For recrystallization of PyBOP and PyBroP, and a similar observation of pyrolidine-containing side-product formation, see: Alsina, J.; Barany, G.; Albericio, F.; Kates, S. A. Lett. Peptide Sci. 1999, 6, 243.
36. PyBOP is slightly less efficient than PyBroP since it forms two transition intermediates with 2, the more reactive 4 (Table 2) and the less reactive 2-O-(benzotriazol-1-yl)-pyrimidine which can be isolated from the incomplete coupling reaction.
37. It is interesting to note that the less effective solvents, e.g. MeCN, DCM and DMF led to homogeneous reactions, while the more effective solvents, e.g. dioxane, THF and DME, resulted in heterogeneous reactions. Dioxane seems to cause a slightly less heterogeneous, faster and cleaner reaction than THF and DME.
38. It is not surprising that DMF was the least effective solvent for the targeted coupling reaction, since it is known that DMF can form formamidines with amines in the presence of PyBroP; see: Delarue, S.; Sergheraert, C. Tetrahedron Lett. 1999, 40, 5487.
39. (a) Schreiber, S. L. Science 2000, 287, 1964.
40. (b) Burke, M. D.; Lalic, G. Chem. Biol. 2002, 9, 535.
41. (c) Burke, M. D.; Berger, E. M.; Schreiber, S. L. Science 2003, 302, 613.